1. Introduction {#sec1}
===============

CD4^+^CD25^+^ regulatory T cells (T~reg~ cells) are expanded in murine tumor models, and their deletion can lead to complete tumor regression \[[@B1]\]. In humans, T~reg~ cells are mostly enriched in the CD4^+^CD25^high^ T-cell population \[[@B2]\]. We and others have reported increased frequencies of CD4^+^CD25^high^FOXP3^+^ T~reg~ cells in cancer patients \[[@B1], [@B3]\]. However, the expansion of T~reg~ cells based on the assessment of CD25 is likely to underestimate the true expansion since FOXP3^+^ T cells are also present in the CD25^−/low^ fraction \[[@B4], [@B5]\]. Furthermore, molecular and functional characterization of this population is hampered by the inability to separate CD25^+^ T~reg~ cells from activated effector T cells. Two recent studies, however, have shown that reciprocal expression of the IL7 receptor (CD127) on FOXP3^+^ T~reg~ cells is most likely a more specific way to quantify FOXP3^+^ T~reg~ cells \[[@B5], [@B6]\]. This has been adopted lately for the quantification of T~reg~ cells in solid tumors \[[@B7]--[@B10]\] and hematologic malignancies \[[@B11]--[@B13]\], with one of the reports establishing CD127 as an even superior marker for the identification of T~reg~ cells in cancer patients \[[@B9]\]. However, no systematic analysis has been undertaken to establish CD127 as a superior marker for T~reg~-cell enumeration in cancer patients, and only one initial report of malignant melanoma patients has addressed reciprocal expression of CD127 and FOXP3 on T~reg~ cells in cancer patients independently of CD25 \[[@B9]\]. It is, therefore, necessary to determine whether CD127 is also a better marker for enumerating FOXP3^+^ T~reg~ cells in cancer patients in general by comparing T~reg~ cells numbers in a larger number of different tumor subtypes. Besides the integration of CD25^low/−^ FOXP3-expressing T~reg~ cells, analysis of CD127 might, furthermore, clarify contradictory results concerning frequencies as well as prognostic value of T~reg~ cells in cancer patients \[[@B14]--[@B16]\].

Similarly, there is still debate whether human CD4^+^CD25^high^FOXP3^+^ T~reg~ solely belong to the memory T-cell compartment \[[@B17]\]. Valmori et al. were the first to identify a T~reg~-cell population with a naïve phenotype (CCR7^+^CD45RA^+^), which they termed natural naïve T~reg~ cells \[[@B18]\]. As expected, the frequency of these naïve T~reg~ cells was relatively low in healthy individuals \[[@B19]\]. More recently, Seddiki et al. have described the persistence of a population of naïve CD45RA^+^ T~reg~ cells in adult life \[[@B20]\], which was further characterized by resistance to CD95L-induced cell death \[[@B21]\]. Recent data further supports that a population of naïve T~reg~ cells exist in healthy individuals that exerts suppressive function \[[@B22]\]. So far, our own observations suggested an increased frequency of naïve CD4^+^CD25^high^FOXP3^+^ T~reg~ cells in MM and MGUS \[[@B23]\]. However, previous findings were restricted to the CD4^+^CD25^high^ subpopulation excluding a significant fraction of T~reg~ cells from analysis. With the emergence of CD127 as a new marker separating T~reg~ cells from conventional T cells, the question whether the expanded T~reg~ cells in cancer patients are mainly antigen-experienced memory cells or also naïve T~reg~ cells needs reevaluation.

Here, we present clear evidence that FOXP3^+^ T cells derived from patients with CLL, MGUS, MM, follicular lymphoma (FL), Hodgkin\'s disease (HD), and colorectal cancer (CRC) are lacking CD127. This newly defined fully functional CD4^+^CD127^low^FOXP3^+^ T~reg~-cell population is expanded in all tumor entities as well as the premalignant MGUS supporting the hypothesis of increased T~reg~ cells as a rather early event during tumor development. Moreover, we demonstrate a significant increase of naïve CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in peripheral blood of cancer patients while we could not detect an increase in lymph node biopsies of lymphoma patients. Finally, these data strongly support the assessment of CD127 expression---instead of CD25---in combination with FOXP3 for a more precise enumeration of T~reg~ cells in malignant diseases while functional characterization still relies on the combination of CD127 and CD25.

2. Material and Methods {#sec2}
=======================

2.1. Patients and Clinical Parameters {#sec2.1}
-------------------------------------

Following approval by the institutional review board of the University of Cologne, peripheral blood from 10 healthy individuals, 7 MGUS, 10 MM, 10 CLL and 6 patients with CRC (2 time points at least 1 month apart) was obtained after informed consent. For the assessment of T~reg~ cell numbers in lymph node biopsies, lymph nodes from 7 healthy donors, 6 patients with HD, and 7 patients with FL were analyzed following approval by the institutional review board of the University of Cologne. Patients were either untreated or had not received cytoreductive treatment for a period of at least 1 month prior to investigation. Characteristics of the patients studied are summarized in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}.

2.2. Antibodies and FACS Analysis {#sec2.2}
---------------------------------

Phenotype of T cells was defined by flow cytometry using the following antibodies: CD45RA-PE-Cy5 (HI100), CD127-PE (hIL-7R-M21), CD4-APC-Cy7 (RPA-T4), CD25-PE-Cy7 (M-A251, all from Becton Dickinson), CCR7-FITC (150503, R&D) as well as the corresponding isotype control antibodies. Intracellular staining for FOXP3 was performed with FOXP3-APC (PCH101, eBioscience) according to the manufacturer\'s recommendations \[[@B23]\]. Samples were acquired on a FACS LSR II and analyzed with FlowJo software (TreeStar Inc). Frequencies of CD4^+^CD127^low^FOXP3^+^ T cells are shown as percent values of CD4^+^ T cells.

2.3. Isolation of CD4^+^CD127^low^CD25^+/low^ and CD4^+^CD127^+^CD25^−^ T Cells and Assessment of Inhibitory Function {#sec2.3}
---------------------------------------------------------------------------------------------------------------------

To assess the suppressive activity of CD4^+^CD127^low^CD25^+/low^ T cells, a modified MLR was performed as previously described \[[@B23]\]. Briefly, CD4^+^CD127^low^CD25^+/low^ and CD4^+^CD127^+^CD25^−^ T cells were stained with CD4, CD25, and CD127 mAb and sorted on a FACSDiVa or FACS Aria III (both BD Biosciences) and incubated for 20 hours with 10 U/mL IL-2 (Proleukin) and 0.5 *μ*g/mL anti-CD3 (OKT3) in X-VIVO 15 (BioWhittakker) \[[@B24]\]. Subsequently, CD4^+^CD127^+^CD25^−^ T cells were stained with 5,6-Carboxyfluorescin-Diacetat-Succinimidyl-Ester (CFSE, Sigma-Aldrich) and stimulated in X-VIVO 15 supplemented with 10% fetal calf serum, 100 U/mL penicillin/streptomycin and 2 mM glutamine (Invitrogen) with magnetic beads (Dynal Biotech,) coated with 5% anti-CD3, 14% anti-CD28 (9.3), and 81% anti-MHC class I (W6/32) at a ratio of 3 : 1 (cells : beads). To assess inhibitory capacity of T~reg~ cells from cancer patients, autologous CD4^+^CD127^low^CD25^+/low^ T~reg~ cells were added at a 1 : 1 ratio to the culture, and the proliferation of CD4^+^CD127^+^CD25^−^ T cells was determined by assessing CFSE dilution after four days of culture as described previously \[[@B23]\].

2.4. RNA Preparation and Quantitative Real-Time PCR {#sec2.4}
---------------------------------------------------

For analysis of CD127 mRNA expression, CD4^+^CD25^−^ and CD4^+^CD25^high^ T cells from five healthy donors and five CLL patients were purified as previously described \[[@B24]\]. The described technique is optimized for the isolation of human CD4^+^CD25^high^ T cells with high purity \[[@B23], [@B24]\]. Cells were reanalyzed after sorting and routinely showed \>95% purity. Subsequently, the cells were lysed in TRIzol reagent (Invitrogen). 50--100 ng RNA were reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Penzberg, Germany). Rt-PCR was performed with the LightCyclerTaqman master kit and Universal ProbeLibrary Assay on a Light Cycler 480 II. Analysis was performed using Light-Cycler3 and RelQuant software using a calibrator normalized relative quantification based on *β*-2 microglobulin (B2M) expression. Primers used: CD127 forward, 5′- AAAGTTTTAATGCACGATGTAGCTT-3′; CD127 reverse, 5′- TGTGCTGGATAAATTCACATGC-3′; Probe 72; B2M forward, 5′- TTCTGGCCTGGAGGCTAT-3′; B2M reverse, 5′TCAGGAAATTTGACTTTCCATTC-3′; Probe 42.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Comparison between paired or unpaired groups was performed using the appropriate Student\'s *t*-test. A *P*-value \< 0.05 was defined as statistically significant. Due to the explorative nature of this study, no multiplicity adjustment procedures were performed. All statistical analyses were performed using the SPSS statistical software package (SPSS 19.0, SPSS Inc.).

3. Results {#sec3}
==========

3.1. Downregulation of CD127 mRNA Expression in CD4^+^CD25^high^ T~reg~ Cells from CLL Patients {#sec3.1}
-----------------------------------------------------------------------------------------------

As CD25 is not solely expressed on T~reg~ cells but also on activated conventional CD4^+^ T cells, and the downregulation of CD127 expression in CD4^+^CD25^high^ FOXP3^+^ T~reg~ cells from healthy donors has been reported \[[@B5], [@B6]\], we first assessed if CD127 downregulation is also apparent in CD4^+^CD25^high^ T~reg~ cells from cancer patients. We detected a significant downregulation of CD127 mRNA expression in CD4^+^CD25^high^ T cells from healthy donors (*n* = 5) as well as CLL patients (*n* = 5, *P* \< 0.05, [Figure 1(a)](#fig1){ref-type="fig"}) by quantitative PCR indicating that CD127 expression might also be used to specifically identify CD4^+^FOXP3^+^ T~reg~ cells in cancer patients.

3.2. Coassessment of CD127 and FOXP3 for the Enumeration of Human T~reg~ Cells {#sec3.2}
------------------------------------------------------------------------------

Next the expression of CD127 in relation to FOXP3 and CD25 was evaluated by flow cytometry on CD4^+^ T cells. Gating on CD4 and CD25 with subsequent analysis of the CD4^+^CD25^high^ T~reg~-cell population for expression of FOXP3 and CD127 confirmed the downregulation of CD127 in CD4^+^CD25^high^FOXP3^+^ T~reg~ cells on protein level in healthy individuals ([Figure 1(b)](#fig1){ref-type="fig"}). However, assessing coexpression of CD127 and FOXP3 by CD4^+^ T cells without gating beforehand on the CD4^+^CD25^high^ T-cell population clearly revealed a significantly higher percentage of cells expressing FOXP3 but lacking CD127 ([Figure 1(c)](#fig1){ref-type="fig"}). Subsequent analysis of the CD127^low^FOXP3^+^ T~reg~-cell population for expression of CD25 demonstrated that gating on CD127 and FOXP3 identifies not only CD4^+^CD25^high^ T~reg~ cells but also T~reg~ cells expressing only low levels of CD25 ([Figure 1(c)](#fig1){ref-type="fig"}). The identification of this subpopulation of T~reg~ cells is of specific interest as up to now only T~reg~ cells expressing high amounts of CD25 were accessible to functional analysis.

3.3. Increase of CD4^+^CD127^low^FOXP3^+^ T~reg~ Cells in Cancer Patients {#sec3.3}
-------------------------------------------------------------------------

Inclusion of the CD25^low^ T~reg~-cell subpopulation in the enumeration of T~reg~ cells by defining human T~reg~ cells as CD4^+^CD127^low^FOXP3^+^ demands the reassessment of T~reg~-cell frequencies in cancer patients as the actual frequencies were probably underestimated until now. Comparison of healthy individuals with cancer patients revealed elevated levels of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in cancer and MGUS patients, as exemplified for individual patients in Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}. In total, frequencies of T~reg~ cells derived from peripheral blood of 12 patients with CRC, 10 CLL patients, 7 MGUS, and 10 MM patients as well as 10 healthy individuals were evaluated. In addition, lymph node biopsies from 7 patients with follicular lymphoma, 6 patients with Hodgkin\'s disease, and 7 reactive lymph nodes from healthy individuals were assessed for expanded T~reg~-cell numbers. Gating on CD4 and CD25 with subsequent gating on FOXP3 confirmed the already described increase of T~reg~ cells in patients with CRC, CLL, MGUS, MM, FL, and HD (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"} and Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). More important, when gating on FOXP3 and CD127 without using CD25 as primary inclusion criteria, frequencies of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in controls (4.1% ± 0.7%) were similar to previously published results ([Figure 3(c)](#fig3){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}) \[[@B2], [@B5], [@B6], [@B24]\]. In contrast, individuals with CRC (7.2% ± 2.4%, *P* \< 0.005), CLL (8.9% ± 4.0%, *P* \< 0.005), as well as MM (11.7% ± 5.4%, *P* \< 0.005) showed significantly increased frequencies of CD127^low^FOXP3^+^ T~reg~ cells compared to healthy individuals ([Figure 3(c)](#fig3){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}). Even in MGUS patients, a significantly higher frequency of T~reg~ cells (6.0% ± 1.8%, *P* \< 0.05) was observed ([Figure 3(c)](#fig3){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}), which is indicative of T~reg~-cell expansion as an early event in tumorigenesis. Similarly, we observed significantly increased frequencies of CD127^low^FOXP3^+^ T~reg~ cells in patients with FL (21.8% ± 8.0%, *P* \< 0.01) and HD (24.4% ± 13.1%, *P* \< 0.05) in comparison to reactive lymph node specimens from healthy individuals (10.1% ± 4.4, [Figure 3(d)](#fig3){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}). Moreover, the percentage of FOXP3^+^ cells within the CD4^+^CD127^low^ T-cell population was always higher than within the CD4^+^CD25^high^ population, suggesting that previous data only assessing a CD4^+^CD25^high^ phenotype have underestimated the absolute increase of FOXP3^+^ T~reg~ cells in cancer patients (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}).

3.4. CD4^+^CD127^low^CD25^+/low^ T~reg~ Cells are Fully Functional in Cancer Patients {#sec3.4}
-------------------------------------------------------------------------------------

As intracellular FOXP3 staining is not applicable for functional analysis of T~reg~ cells, classification of FOXP3^+^ T~reg~ cells based solely on cell surface markers is necessary. The characterization of FOXP3^+^ T~reg~ cells was best achieved when combining CD127 and CD25 (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"}). We, therefore, used this combination of cell surface markers to sort T~reg~ cells for functional analysis. Staining for FOXP3 expression after sorting routinely showed purities of CD4^+^CD127^low^FOXP3^+^CD25^+/low^ T~reg~ cells \>95 percent ([Figure 4(b)](#fig4){ref-type="fig"}). To determine whether the CD4^+^CD127^low^CD25^+/low^ T~reg~ cells from cancer patients are functional, we used an *in vitro*suppression assay. When activated with CD3/CD28 beads conventional CD4^+^CD127^+^CD25^−^ T cells, but not CD4^+^CD127^low^CD25^+/low^ T~reg~ cells, proliferate strongly. In the presence of CD4^+^CD127^low^CD25^+/low^ T~reg~ cells, this proliferation is suppressed ([Figure 4(c)](#fig4){ref-type="fig"}). These data clearly demonstrate that CD4^+^CD127^low^CD25^+/low^ T cells are FOXP3^+^ and that these cells are fully functional in CRC patients.

3.5. Naïve CD4^+^CD127^low^FOXP3^+^ T~reg~ Cells are Increased in Peripheral Blood of Cancer Patients {#sec3.5}
-----------------------------------------------------------------------------------------------------

In healthy individuals, T~reg~ cells have been shown to exist at all differentiation states, namely, naïve, central, and effector memory T~reg~ cells \[[@B18], [@B20], [@B25]\]. To determine which T~reg~-cell subpopulation is responsible for the increase of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in cancer patients, we determined the frequency of naïve, central, and effector memory cells within the T~reg~-cell compartment from healthy individuals, CRC, CLL, MGUS, and MM patients ([Figure 5(a)](#fig5){ref-type="fig"}) and compared these data with those previously described for CD4^+^CD25^high^ T~reg~ cells in healthy individuals as well as MGUS and MM patients \[[@B18], [@B23]\]. In healthy individuals, naïve CCR7^+^CD45RA^+^CD4^+^CD127^low^FOXP3^+^ T~reg~ cells were hardly detectable (Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}). T~reg~ cells were almost exclusively of memory phenotype (Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}). In contrast, in peripheral blood of CRC, CLL, and MM patients, a significant expansion of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells with a naïve phenotype was observed (Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}). The expansion of naïve T~reg~ cells was apparent as part of the T~reg~-cell pool as well as in relation to the total number of CD4^+^ T cells in cancer patients. This increase in naïve T~reg~ cells was further accompanied by an expansion of T~reg~ cells with a central as well as effector memory phenotype in all patient groups (Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}). Interestingly, the observed expansion of naïve CD4^+^CD127^low^FOXP3^+^ T~reg~ cells was also detectable in MGUS patients (Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}) further underlining that frequencies of naïve T~reg~ cells increase rather early during tumor development and progression. When assessing subpopulations of T~reg~ cells in lymph node specimens, we observed a predominance of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells with a central-memory phenotype, with a significantly expanded population of central-memory T~reg~ cells apparent in patients with FL and HD ([Figure 5(d)](#fig5){ref-type="fig"}). In addition, we could also detect an increase in effector-memory T~reg~ cells ([Figure 5(d)](#fig5){ref-type="fig"}) while the pool of naïve T~reg~ cells was basically absent independent if reactive or diseased lymph nodes were analyzed ([Figure 5(d)](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Expansion of CD4^+^CD25^high^ T~reg~ cells within the tumor microenvironment and peripheral blood has so far been accepted as a hallmark of cancer \[[@B1], [@B26], [@B27]\]. Moreover, augmented T~reg~-cell frequencies have been linked to tumor stage, prognosis, and survival \[[@B1], [@B26], [@B27]\]. We present new evidence that the increase of T~reg~ cells in cancer was even underestimated previously due to suboptimal classification of T~reg~ cells. Integrating analysis of FOXP3 with the cell-surface molecule CD127 clearly demonstrates that significantly higher numbers of CD127^low^FOXP3^+^ T~reg~ cells are expanded in cancer patients in general. The assessment of CD127 instead of CD25 is clearly superior in enumerating T~reg~ cells in the diseased state.

Natural T~reg~ cells have been described as CD4^+^CD25^+^ T cells in mice \[[@B28]\], and initial reports in cancer patients relied solely on the assessment of CD4 and CD25 expression for the identification of T~reg~ cells \[[@B3], [@B29]\]. Only since the identification of the transcription factor FOXP3 lineage-specific marker of T~reg~ cells a more specific characterization of T~reg~ cells is possible \[[@B28]\]. In murine models, FOXP3 expression is strongly associated with the CD25^+^ T~reg~-cell population. However, even the inclusion of FOXP3 assessment has been interpreted differentially when assessing frequencies of T~reg~ cells in healthy individuals and cancer patients \[[@B23], [@B30]\]. The analysis of T~reg~ cells in humans has been further complicated as several studies reported FOXP3^+^ cells within the CD4^+^CD25^low^ or even CD4^+^CD25^−^ population \[[@B5]\], and even the reprogramming of T~reg~ cells into effector T cells has been reported \[[@B31]\]. Therefore, a more specific definition of T~reg~ cells based on unique or additional T~reg~-cell marker molecules is urgently needed. The introduction of CD127 as a new marker to distinguish T~reg~ cells from conventional T cells is an important improvement and will help to clarify several previous conflicting results in human T~reg~-cell biology, particularly in cancer patients.

Several recent studies have adopted the approach to use CD127, CD25, and FOXP3 for the quantification of T~reg~ cells in tumor-bearing individuals and could demonstrate increased numbers of CD4^+^CD25^high^CD127^low^ T~reg~ cells in patients with solid tumors \[[@B7]--[@B10]\] and hematologic malignancies \[[@B11]--[@B13]\]. However, the majority of these reports focused solely on the enumeration of the T~reg~-cell compartment while at the same time focusing on only one tumor subtype. Only one study assessed T~reg~-cell numbers in more than one tumor subtype showing similar numbers of T~reg~ cells for all gastrointestinal tumor subtypes analyzed \[[@B8]\]. Furthermore, these studies did not systematically compare possible marker combinations to establish the most suitable approach to identify T~reg~ cells. This was analyzed in more detail in only one of the reports with the combination of CD127 and FOXP3 being the most appropriate combination to identify T~reg~ cells in patients with malignant melanoma \[[@B9]\].

The integration of CD127 permits to redefine the importance of CD25 expression on human T~reg~ cells. Up to now, high expression of CD25 allowed for an enrichment of CD4^+^ T cells with regulatory properties \[[@B2]\]. However, it is undisputed that neither all human T~reg~ cells are included by this approach nor that activated T cells expressing CD25 are excluded. Zelenay et al. could demonstrate a population of CD4^+^CD25^−^FOXP3^+^ T cells which can upregulate CD25 upon the depletion of all CD25 expressing cells and are able to replace the original T~reg~-cell population \[[@B4]\]. These data were a first hint that the expression of CD25 on T~reg~ cells is similarly regulated like its expression on conventional T cells \[[@B4]\]. Human T~reg~ cells need IL-2 for their survival and proliferation, and expression of the IL2R-*α* chain is certainly a prerequisite for IL-2 to exert its biological function \[[@B32]\]. However, the expression of CD25 is not homogenous and might also be dependent on the activation status and other exogenous factors \[[@B33]\].

Using CD127 and FOXP3 to define human T~reg~ cells demonstrates varying expression of CD25 in the CD4^+^CD127^low^FOXP3^+^ T~reg~-cell population. Additionally, the newly defined T~reg~-cell population comprises of significantly more T~reg~ cells compared to the traditionally defined CD4^+^CD25^high^ T~reg~ cells as demonstrated recently for malignant melanoma \[[@B9]\]. Coassessment of CD127 and FOXP3 to determine T~reg~ cells also resolves the uncertainty to differentiate between activated conventional T cells and T~reg~ cells in patients with active disease. This is of particular importance when only using CD4 and CD25 for the identification of T~reg~ cells in cancer patients, as contamination with effector T cells most frequently occurs when solely these two markers are used for analysis. As functional assessment of the CD4^+^CD127^low^FOXP3^+^ T~reg~-cell population is not possible as FOXP3 cannot be used for live studies of human T~reg~ cells, using expression of CD4, CD25, and CD127 is the best possible approximation. T cells isolated by this approach almost exclusively express FOXP3. Moreover, when isolated from cancer patients, this T~reg~-cell population exerts strong inhibition.

Using a comparative approach analyzing different tumor subtypes from hematologic as well as epithelial origin, we demonstrate that all independent cancer patient groups studied uniformly show an expanded pool of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells. We therefore postulate that expansion of T~reg~ cells is a general phenomenon in cancer patients. Moreover, since MGUS patients already have increased frequencies of T~reg~ cells, it is very likely that expansion of T~reg~ cells is an early event in the development of human tumors. Elevated T~reg~-cell levels might be associated with the progression from premalignant lesions that are still under control of the immune system to the uninhibited growth of malignant tumors.

The findings that naïve T~reg~ cells are increased both in the premalignant state as well as in cancer patients might further support this hypothesis. T~reg~ cells were first identified as antigen-experienced memory cells expressing CD45RO \[[@B2]\]. Only recently the existence of naïve T~reg~ cells in human adults has been reported \[[@B18], [@B20], [@B22], [@B23], [@B34]\], and the naïve T~reg~-cell population can be expanded *in vitro* while retaining its suppressive function \[[@B35], [@B36]\]. However, the physiological function of the naïve T~reg~-cell population remains unclear. Definition of T~reg~ cells as CD4^+^CD127^low^FOXP3^+^ has enabled us to verify the increase of naïve T~reg~ cells in MGUS and MM patients \[[@B23]\] and to extend these findings to CLL and CRC.

The identification of an expanded pool of naïve T~reg~ cells in cancer patients opens new avenues to better understand the role of T~reg~ cells in malignant disease. Memory T~reg~ cells apparently cannot undergo self-renewal \[[@B37]\]. Therefore, the replenishment of an increased memory T~reg~-cell pool by differentiation of naïve T~reg~ cells into memory T~reg~ cells might be an alternative to the recently proposed conversion of conventional memory T cells to T~reg~ cells \[[@B37]\]. In fact, the increased pool of naïve T~reg~ cells with an unaltered frequency of memory T~reg~ cells in premalignant MGUS suggests that expansion of naïve T~reg~ cells is indeed preceding the expansion of memory T~reg~ cells following differentiation during tumor development. Besides the expansion of naïve T~reg~ cells through enhanced self-renewal and differentiation, other mechanisms have been proposed amongst them the interaction of CCR4 on T~reg~ cells with CCL22 released in the tumor microenvironment \[[@B38]\] as well as the conversion of conventional CD4^+^CD25^−^ T cells to T~reg~ cells trough TGF-*β* \[[@B39]\] or prostaglandin E~2~ \[[@B40]\]. How these factors influence the expansion of naïve T~reg~ cells needs further clarification and might in the end result in better strategies to target expanded T~reg~ cells in tumor patients.

In conclusion this study demonstrates that CD4^+^CD127^low^FOXP3^+^ T~reg~ cells are increased in cancer patients. Definition of T~reg~ cells by combining CD127 and FOXP3 has the advantage of including not only T~reg~ cells expressing high levels of CD25 but also T~reg~ cells with low CD25 expression and excluding at the same time activated conventional T cells. Furthermore, the naïve T~reg~-cell population is expanded in all tumor bearing individuals.
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![CD127 mRNA expression in CD4^+^CD25^high^ T~reg~ cells and integration of CD127 in the analysis of human T~reg~ cells. (a) Expression of CD127 mRNA in CD4^+^CD25^high^ T~reg~ cells and conventional CD4^+^CD25^−^ T cells in healthy donors (*n* = 5, control) and CLL patients (*n* = 5, CLL) as determined by qPCR (\*, *P* \< 0.05, Student\'s *t-*test). (b) Gating strategies for analysis of expression of CD127 in CD4^+^CD25^high^FOXP3^+^ T~reg~ cells or (c) CD25 expression in CD4^+^CD127^low^FOXP3^+^ T~reg~ cells.](CDI2011-734036.001){#fig1}

![Frequency of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells. Flow cytometric analysis of CD127 and FOXP3 expression in CD4^+^ T cells from (a) peripheral blood of a representative healthy individual (control) and representative patients with colorectal cancer (CRC), CLL, MGUS, and multiple myeloma (MM) and (b) lymph node biopsies from a healthy individual (reactive) and patients with follicular lymphoma (FL) and Hodgkin\'s diseases (HD).](CDI2011-734036.002){#fig2}

![Assessment of T~reg~-cell frequencies. Frequency of CD4^+^CD25^high^FOXP3^+^ T~reg~ cells in (a) peripheral blood of 10 healthy donors (control), 12 colorectal cancer (CRC), 10 CLL, 7 MGUS, and 10 multiple myeloma (MM) patients and (b) 7 reactive lymph node biopsies from healthy individuals (reactive), 7 patients with follicular lymphoma (FL), and 6 patients with Hodgkin\'s disease (HD). (c) and (d) Frequencies of CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in the respective groups. Error bars represent standard deviation (\*, *P* \< 0.05, Student\'s *t*test).](CDI2011-734036.003){#fig3}

![Functional analysis of CD4^+^CD127^low^CD25^+^ T~reg~ cells in cancer patients. (a) Sorting strategy for isolating CD4^+^CD127^low^CD25^+^ T~reg~ cells (T~reg~) as well as conventional CD4^+^CD127^+^CD25^−^ T cells (T~conv~). (b) Expression of FOXP3 in the corresponding T-cell populations. (c) Percentage of proliferation of CD4^+^CD25^−^CD127^+^ T~conv~ cells (black bar) alone or cultivated with CD4^+^CD127^low^CD25^+^ T~reg~ cells derived from CRC patients (*n* = 4) at a 1 : 1 ratio (white bar) both in the presence of CD3/CD28 mAb coated beads. Error bars represent standard deviation (\*, *P* \< 0.05, Student\'s *t*test).](CDI2011-734036.004){#fig4}

![Assessment of naïve CCR7^+^CD45RA^+^CD4^+^CD127^low^FOXP3^+^ T~reg~ cells. (a) Frequencies of CCR7^+^CD45RA^+^ naïve CD4^+^CD127^low^FOXP3^+^ T~reg~ cells (T~naive~), CCR7^+^CD45RA^−^CD4^+^CD127^low^FOXP3^+^ central memory T~reg~ cells (T~CM~), and CCR7^−^CD45RA^−^CD4^+^CD127^low^FOXP3^+^ effector memory T~reg~ cells (T~EM~) were assessed in peripheral blood using gating on CD127 and FOXP3 with successive gating on CCR7 and CD45RA. (b) Flow cytometric analysis of naïve, central memory, and effector memory CD4^+^CD127^low^FOXP3^+^ T~reg~ cells in peripheral blood from a representative healthy individual (control) as well as representative patients with colorectal cancer (CRC), CLL, MGUS, and multiple myeloma (MM). Frequencies of regulatory T~naive~, T~CM~, and T~EM~ cells were assessed in (c) peripheral blood of CRC (CRC, *n* = 12), CLL (CLL, *n* = 10), MGUS (MGUS, *n* = 7), MM (MM, *n* = 10), and healthy individuals (control, *n* = 10) and (d) 7 reactive lymph node biopsies from healthy individuals (reactive), 7 patients with follicular lymphoma (FL), and 6 patients with Hodgkin\'s disease (HD). Error bars represent standard deviation (\*, *P* \< 0.05, Student\'s *t-*test).](CDI2011-734036.005){#fig5}

###### 

Patient characteristics for T~reg~-cell assessment in peripheral blood.

###### 

\(a\) MGUS (peripheral blood)

  ID   Gender   Age (yr)   Stage   Therapy   Paraprotein   T~reg~ (%)
  ---- -------- ---------- ------- --------- ------------- ------------
  1    M        37         MGUS    no tx     IgG/*λ*       3.6
  2    F        84         MGUS    no tx     IgA/*κ*       7.0
  3    F        86         MGUS    no tx     IgG/*κ*       7.5
  4    F        62         MGUS    no tx     IgA           6.0
  5    M        52         MGUS    no tx     n.a.          6.8
  6    F        79         MGUS    no tx     n.a.          2.4
  7    M        65         MGUS    no tx     IgM/*κ*       8.0

###### 

\(b\) Multiple myeloma (peripheral blood)

  ID   Gender   Age (yr)   Stage     Therapy            Paraprotein   T~reg~ (%)
  ---- -------- ---------- --------- ------------------ ------------- ------------
  8    M        62         MM I A    M                  IgG/*κ*       16.5
  9    F        39         MM I A    VAD, CAD, M, BMT   IgG/*κ*       7.4
  10   M        59         MM II A   no tx              IgG/*κ*       10.2
  11   F        74         MM I A    no tx              IgG/*λ*       4.5
  12   M        86         MM I A    no tx              IgG/*κ*       6.7
  13   M        60         MM II A   VAD, CAD, M, BMT   IgG/*κ*       16.9
  14   F        52         MM II A   VID, C             IgG/*κ*       4.4
  15   M        59         MM II A   TAD, CAD, M, BMT   IgG/*κ*       8.6
  16   F        67         MM II A   VAD, CAD, M, BMT   IgG/*κ*       22.2
  17   M        53         MM II A   no tx              IgG/*λ*       8.0

###### 

\(c\) Chronic lymphocytic leukemia (peripheral blood)

  ID   Gender   Age (yr)   Stage   Therapy   T~reg~ (%)
  ---- -------- ---------- ------- --------- ------------
  18   m        72         CLL A   no tx     6.1
  19   m        62         CLL A   no tx     5.7
  20   f        73         CLL A   no tx     5.6
  21   m        60         CLL B   no tx     9.8
  22   f        55         CLL B   no tx     10.6
  23   m        73         CLL B   no tx     16.4
  24   m        64         CLL B   no tx     7.4
  25   m        39         CLL C   no tx     15.3
  26   m        60         CLL C   no tx     6.2
  27   m        54         CLL C   no tx     6.4

###### 

\(d\) Colorectal cancer (peripheral blood)

  ID   Gender   Age (yr)   Stage   Primary tumor   Sites of metastases                                T~reg~ (%)
  ---- -------- ---------- ------- --------------- -------------------------------------------------- ------------
  28   f        43         D       Rectum          Liver, bone, pararectal, para-aortal lymph nodes   7.5/10.4
  29   f        32         D       Colon           Liver, spleen, ovaries, pelvis, peritoneum         5.7/9.3
  30   m        57         D       Rectum          Lung                                               5.7/9.9
  31   m        66         D       Colon           Liver                                              5.0/6.2
  32   m        75         D       Colon           Liver                                              9.0/4.8
  33   f        44         D       Colon           Liver                                              9.9/3.3

###### 

\(e\) Healthy donors (peripheral blood)

  ID   Gender   Age (yr)   T~reg~ (%)
  ---- -------- ---------- ------------
  34   m        66         5.4
  35   m        67         6.6
  36   m        55         3.9
  37   m        50         6.5
  38   m        47         4.5
  39   m        46         3.5
  40   m        46         4.8
  41   m        62         4.1
  42   m        45         2.6
  43   f        44         4.0

Patient characteristics including gender, age at analysis, Durie and Salmon, Binet or Dukes stage, first diagnosis, primary tumor, sites of metastases, therapy, paraprotein, and frequency of T~reg~ cells. (f: female, m: male; therapy: A: Doxorubicin, BMT: autologous bone-marrow transplantation, C: Cyclophosphamide, I: Idarubicin, M: Melphalan, V: Vincristine, D: Prednisone, T: Thalidomide, no tx: no therapy, n.a.: not accessible.)

###### 

Patient characteristics for T~reg~-cell assessment in lymph node biopsies.

###### 

\(a\) Follicular lymphoma (lymph node)

  ID   Gender   Age (yr)   Stage   Therapy   T~reg~ (%)
  ---- -------- ---------- ------- --------- ------------
  44   m        59         FL I    no tx     23.9
  45   m        46         FL I    no tx     13.4
  46   f        58         FL I    no tx     26.8
  47   m        73         FL II   no tx     19.6
  48   f        66         FL II   no tx     20.0
  49   m        59         FL II   no tx     13.2
  50   m        57         FL II   no tx     22.5
  51   m        65         FL II   no tx     37.5

###### 

\(b\) Hodgkin\'s disease (lymph node)

  ID   Gender   Age (yr)   Entity    Therapy   T~reg~ (%)
  ---- -------- ---------- --------- --------- ------------
  52   f        53         HD (ns)   no tx     37.8
  53   m        44         HD (ns)   no tx     16.8
  54   m        51         HD (ns)   no tx     43.9
  55   m        19         HD (ns)   no tx     18.5
  56   m        34         HD (ns)   no tx     16.9
  57   f        25         HD (mc)   no tx     12.4

###### 

\(c\) Healthy donors (reactive lymph nodes)

  ID   Gender   Age (yr)   T~reg~ (%)
  ---- -------- ---------- ------------
  58   m        35         4.9
  59   f        18         11.7
  60   f        17         4.9
  61   m        22         9.7
  62   f        45         16.7
  63   m        39         8.9
  64   m        24         14.0

Patient characteristics including gender, age at analysis, first diagnosis, therapy, and frequency of T~reg~ cells. (f: female, m: male; no tx: no therapy; mc: mixed cellularity; ns: nodular sclerosing).

###### 

Assessment of T~reg~-cell frequencies in peripheral blood.

                                       Control         Colon           CLL           MGUS            MM                                                          
  ------------------------------------ --------------- --------------- ------------- --------------- ------------- --------------- ------------ ---------------- -------------
  CD4^+^CD127^low^                     4.6 (1.3)       7.6 (1.5)       \<0.001       8.3 (2.5)       \<0.005       5.4 (1.3)       n.s.         11.2 (5.9)       \<0.01
  CD4^+^CD127^low^FOXP3^+^             **4.1 (0.7)**   **7.2 (2.4)**   **\<0.005**   **8.9 (4.0)**   **\<0.005**   **6.0 (1.8)**   **\<0.05**   **11.7 (5.4)**   **\<0.005**
  CD4^+^CD127^low^FOXP3^+^CD25^high^   2.5 (0.6)       4.3 (1.6)       \<0.005       4.7 (2.7)       \<0.05        3.9 (1.3)       \<0.05       7.1 (4.9)        \<0.05
  CD4^+^CD25^high^                     2.8 (0.9)       7.6 (1.2)       \<0.001       6.4 (1.8)       \<0.001       4.5 (1.1)       \<0.05       9.0 (5.3)        \<0.01
  CD4^+^CD25^high^CD127^low^           2.9 (0.9)       4.5 (1.2)       \<0.005       4.5 (2.0)       \<0.05        3.5 (1.3)       n.s.         7.0 (5.1)        \<0.05
  CD4^+^CD25^high^FOXP3^+^             2.1 (0.8)       4.2 (1.2)       \<0.001       3.6 (1.7)       \<0.05        2.5 (0.6)       n.s.         6.3 (4.5)        \<0.05
  CD4^+^FOXP3^+^                       2.8 (0.9)       4.7 (2.1)       \<0.05        4.7 (2.4)       \<0.05        3.6 (1.1)       n.s.         7.7 (5.1)        \<0.05

Definition of subpopulations based on expression of CD25, CD127, and FOXP3 (SD: standard deviation, n.s.: not significant).

###### 

Assessment of T~reg~-cell frequencies in lymph node biopsies.

                                       Control          FL               HD                             
  ------------------------------------ ---------------- ---------------- ------------ ----------------- ------------
  CD4^+^CD127^low^                     54.7 (23.1)      68.6 (15.8)      \>0.05       68.0 (12.7)       \>0.05
  CD4^+^CD127^low^FOXP3^+^             **10.1 (4.4)**   **21.8 (8.0)**   **\<0.01**   **24.4 (13.1)**   **\<0.05**
  CD4^+^CD127^low^FOXP3^+^CD25^high^   3.1 (1.9)        11.7 (5.5)       \<0.005      6.4 (2.3)         \<0.05
  CD4^+^CD25^high^                     5.1 (2.9)        13.8 (7.1)       \<0.05       11.2 (3.3)        \<0.005
  CD4^+^CD25^high^CD127^low^           4.1 (3.0)        16.3 (7.1)       \<0.005      11.3 (5.2)        \<0.05
  CD4^+^CD25^high^FOXP3^+^             2.9 (2.6)        10.0 (5.4)       \<0.01       5.6 (1.2)         \<0.05
  CD4^+^FOXP3^+^                       10.3 (5.5)       19.4 (8.5)       \<0.05       23.4 (12.0)       \<0.05

Definition of subpopulations based on expression of CD25, CD127, and FOXP3 (SD: standard deviation, n.s.: not significant).

[^1]: Academic Editor: D. Craig Hooper
